Skip to main content Help with accessibility Skip to main navigation

Canagliflozin

Indication

 In combination therapy for treating type 2 diabetes (NICE TA315)

NICE TA315 - Canagliflozin in combination therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Suitable for initiation in primary care in line with NICE restrictions (see background paragraph)
Green

Brand:

Invokana®

Nice TA:

315

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Endocrine system

Background

If a person needs to take 2 antidiabetic drugs, canagliflozin is recommended as a possible treatment for people with type 2 diabetes when taken with a drug called metformin, only if the person:
  • cannot take a type of drug called a sulfonylurea or
  • is at significant risk of hypoglycaemia or its consequences.
If a person needs to take 3 antidiabetic drugs, canagliflozin is recommended as a possible treatment when taken with either metformin and a sulfonylurea, or metformin and a type of drug called a thiazolidinedione.
Canagliflozin is recommended as a possible treatment taken with insulin, with or without other antidiabetic drugs.
The LSCMMG recommends canagliflozin as the 2nd line ““gliflozin”” (1st line dapagliflozin or empagliflozin).

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Supporting documents:

Decisions of Lancashire local decision making groups

Pending
Green
Green
Pending
Green
Green
Pending
Pending
What do the colours mean?

Last Updated: 01 - Jun - 2014